Evidence map›Paper›PMID 36962162›Full record

ArticlePLOS global public health2022

Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery.

Julie Garon Carlton, Joan Marembo, Portia Manangazira, Maxwell Rupfutse, Adelaide Shearley, Egnes Makwabarara, Anna Hidle, Anagha Loharikar

Open access · goldFull text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Julie Garon CarltonCDC Foundation, Atlanta, GA, United States of America.ORCID https://orcid.org/0000-0001-9816-9645
Joan MaremboExpanded Program on Immunization, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.ORCID https://orcid.org/0000-0002-4326-4853
Portia ManangaziraEpidemiology and Disease Control, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.ORCID https://orcid.org/0000-0003-0347-3500
Maxwell RupfutseWorld Health Organization Zimbabwe, Harare, Zimbabwe.
Adelaide ShearleyJohn Snow, Inc. Zimbabwe, Harare, Zimbabwe.
Egnes MakwabararaUNICEF Zimbabwe, Harare, Zimbabwe.
Anna HidleCDC Foundation, Atlanta, GA, United States of America.ORCID https://orcid.org/0000-0003-1890-1053
Anagha LoharikarGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Centers for Disease Control and Prevention · USMinistry of Health and Child Welfare · ZWCDC Foundation · USWorld Health Organization - Zimbabwe · ZW

Funding

World Health Organization 001
6 · The paper itself

Abstract

The World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's second dose was concurrently delivered with the single cohort's first dose. We interviewed national-level key informants, reviewed written materials, and observed vaccination sessions to document HPV vaccine introduction in Zimbabwe and identify best practices and challenges. Key informants included focal persons from government health and education ministries, in-country immunization partners, and HPV Vaccine Strategic Advisory Group members. We conducted a desk review of policy/strategy documents, introduction plans, readiness reports, presentations, and implementation tools. Vaccination sessions were observed in three provinces during the 2019 campaign. Key informants (n = 8) identified high cervical cancer burden, political will, vaccine availability, donor financing, and a successful pilot program as factors driving the decision to introduce the HPV vaccine nationally. The school-based delivery strategy was well accepted, with strong collaboration between health and education sectors and high community demand for vaccine identified as key contributors to this success. Challenges with transitioning from a multiple age-based to single grade- and age-based target population as well as funding shortages for operational costs were reported. Zimbabwe's first multiple cohort, school-based HPV vaccination campaign was considered successful-primarily due to strong collaboration between health and education sectors and political commitment; however, challenges vaccinating overlapping cohorts in the 2019 campaign were observed. Integration with existing health and vaccination activities and continued resource mobilization will ensure sustainability of Zimbabwe's HPV vaccination program in the future.

Identifiers

PMID36962162
PMCPMC10021852
OpenAlexW4226165280

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read4
reference markers read2
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.